Skip to main
PYPD
PYPD logo

PolyPid (PYPD) Stock Forecast & Price Target

PolyPid (PYPD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PolyPid Ltd is a clinical-stage biopharmaceutical company focused on developing its proprietary PLEX-based drug delivery technology, with significant potential for addressing surgical site infections (SSI) through its primary candidate, D-PLEX100, which has shown promising efficacy in a Phase 3 clinical study. Recently, the company secured approximately $26.7 million in funding from a new agreement with shareholders, enabling it to efficiently plan a pre-New Drug Application (NDA) meeting with the FDA and paving the way for a potential NDA filing for D-PLEX100 in the first half of 2026. These developments enhance PolyPid's financial stability and the timely progression of its product candidates, creating a solid foundation for future growth and success in the biopharmaceutical market.

Bears say

PolyPid Ltd faces significant risks regarding the efficacy of its product candidates, as there is a possibility that the company's agents may not yield statistically significant results in clinical studies, which would greatly diminish the perceived value of these products. Additionally, even with successful clinical outcomes, the likelihood of failure to gain approval from regulatory agencies could further erode PolyPid’s value. Compounding these issues, the complexity surrounding patent procedures raises concerns about potential revenue erosion starting in 2036, adding to the company's uncertain financial outlook.

PolyPid (PYPD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PolyPid (PYPD) Forecast

Analysts have given PolyPid (PYPD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PolyPid (PYPD) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PolyPid (PYPD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.